Thursday, 15 October 2026European Markets

SPBK1 RINGERIKE And VOSS VEKSEL OGLAND Have A High Dividend Yield And Return On Equity In The Financial Services Sector.

Loading stream...

(VIANEWS) - SPBK1 RINGERIKE (RING.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Financial Services sector.

Financial Asset Price Forward Dividend Yield Return on Equity
SPBK1 RINGERIKE (RING.OL) kr300.00 6.73% 11.09%
VOSS VEKSEL OGLAND (VVL.OL) kr266.00 5.34% 10.95%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. SPBK1 RINGERIKE (RING.OL)

6.73% Forward Dividend Yield and 11.09% Return On Equity

SpareBank 1 Ringerike Hadeland, a regional savings bank, provides various banking products and services to private and corporate customers in Norway. The company accepts various deposits, including savings, current, deposit, and currency accounts. It also provides business, vehicle, and construction loans; financing services, such as agricultural operating credit, factoring, overdraft, and leasing; bank guarantees; insurance products, including business, personal, and agricultural insurance products; pension products; and savings and investment products. In addition, the company offers debit and credit cards, as well as mobile and online banking services. Further, it provides real estate brokerage services; and accounting, payroll, and counselling services. The company offers its services through its digital platforms and customer centers. SpareBank 1 Ringerike Hadeland was founded in 1833 and is headquartered in Hønefoss, Norway.

Earnings Per Share

As for profitability, SPBK1 RINGERIKE has a trailing twelve months EPS of kr30.24.

PE Ratio

SPBK1 RINGERIKE has a trailing twelve months price to earnings ratio of 9.92. Meaning, the purchaser of the share is investing kr9.92 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.09%.

Moving Average

SPBK1 RINGERIKE's worth is above its 50-day moving average of kr295.39 and above its 200-day moving average of kr298.12.

Revenue Growth

Year-on-year quarterly revenue growth grew by 19%, now sitting on 1.12B for the twelve trailing months.

More news about SPBK1 RINGERIKE.

2. VOSS VEKSEL OGLAND (VVL.OL)

5.34% Forward Dividend Yield and 10.95% Return On Equity

Voss Veksel- og Landmandsbank ASA provides banking products and services to private individuals and companies in Norway. The company offers saving accounts; car and other vehicle, home, small, and construction loans; overdrafts facilities; leasing services; bank guarantees; bank and payment cards; insurance products; and online and mobile banking services. The company was founded in 1843 and is based in Voss, Norway.

Earnings Per Share

As for profitability, VOSS VEKSEL OGLAND has a trailing twelve months EPS of kr36.21.

PE Ratio

VOSS VEKSEL OGLAND has a trailing twelve months price to earnings ratio of 7.35. Meaning, the purchaser of the share is investing kr7.35 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.95%.

More news about VOSS VEKSEL OGLAND.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com